Chronic Kidney Disease PBMC
Cryopreserved PBMC from clinically confirmed chronic kidney disease donors, processed within 24 hours and stored in CryoStor CS10. Supports research on uremic immune dysfunction: CD14+CD16+ monocyte expansion, T-cell senescence, blunted vaccine responses and innate activation. Stratifiable by KDIGO eGFR stage, dialysis modality and etiology.
Chronic Kidney Disease PBMC for Uremic Immune Dysfunction Research
Chronic Kidney Disease (CKD) Human PBMC are sourced from IRB-consented donors clinically diagnosed with CKD, processed within 24 hours of collection and cryopreserved in CryoStor® CS10. CKD is a progressive organ disease, not an autoimmune one, but the uremic milieu produces a characteristic and well-described dual immune phenotype: blunted adaptive responses alongside persistent innate activation. These cryopreserved peripheral blood mononuclear cells support immunology, vaccinology and drug-development research in that setting.
Why PBMC for Chronic Kidney Disease
Plasma tells you what has accumulated; PBMC tell you what the immune system has become. Uremic immune dysfunction is a cellular phenotype, and it is only measurable in intact mononuclear cells.
- Monocyte subset skewing — CKD is consistently associated with expansion of CD14+CD16+ intermediate and non-classical monocytes, a shift linked to cardiovascular risk in this population and measurable only by flow cytometry on intact cells.
- T-cell senescence and reduced naive output — declining naive CD4+ T cells with accumulation of CD28-null and terminally differentiated memory T cells is one of the best-documented features of the uremic immune phenotype.
- Impaired vaccine and recall responses — CKD and dialysis donors show blunted antigen-specific responses; PBMC enable ex vivo recall stimulation, ELISpot and proliferation assays that explain why.
- Innate activation despite adaptive suppression — PBMC permit direct measurement of monocyte cytokine release after TLR stimulation, resolving the apparent paradox of a simultaneously inflamed and immunosuppressed patient.
- Uremic solute exposure modelling — cryopreserved PBMC can be cultured with uremic retention solutes to test causality rather than only correlation.
- Transplant-relevant immunology — for donors approaching or following transplantation, PBMC support alloreactivity, mixed lymphocyte and immunosuppression pharmacodynamic assays.
Donor Stratification Available
- KDIGO eGFR category (G1 through G5) and albuminuria category where recorded
- Dialysis modality: non-dialysis CKD, hemodialysis, peritoneal dialysis, or post-transplant
- Primary etiology: diabetic kidney disease, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidney disease
- Immunosuppression status for transplant and glomerular disease donors
- Cardiometabolic comorbidities: type 2 diabetes, hypertension, heart failure
- Matched healthy controls available, age- and sex-matched on request
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed CKD donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- Viability and recovery reported per lot
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified CKD diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies, medications and infectious disease history
- Laboratory values including eGFR and creatinine where available
- Additional CKD-specific data available upon request
Applications
- Immunophenotyping of monocyte subsets and T-cell differentiation states
- Uremic immune dysfunction and immunosenescence research
- Ex vivo TLR and antigen-recall stimulation assays
- Vaccine response and immunogenicity research in CKD and dialysis donors
- Single-cell RNA-seq and CITE-seq of the CKD immune compartment
- Uremic solute exposure and mechanistic culture models
- Drug screening and pharmacodynamic assay development
- Transplant alloreactivity and immunosuppression research
Other Chronic Kidney Disease Specimen Types
- Chronic Kidney Disease Serum
- Chronic Kidney Disease Plasma
- Chronic Kidney Disease Whole Blood
- Chronic Kidney Disease Leukopak
- Diabetic Nephropathy PBMC
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Chronic Kidney Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or regulatory documentation needs. To browse availability across all disease states, visit our human PBMC page.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.